

## ASX Announcement

Melbourne, Australia, 19 April 2024

### Consolidation of Capital

Exopharm Limited (**Exopharm** or the **Company**) (to be renamed Tryptamine Therapeutics Limited) advises that the Company's share register has been updated today.

The share register of Shares and Options has been updated to a ratio of 2.5:1 pursuant to the consolidation of capital as outlined in the Appendix 3A.3 dated 13 March 2024 and as approved by Shareholders of the Company on 11 April 2024.

A copy of the updated share register is provided below:

ASX Security Class	Security Description	# Securities
EX1	ORDINARY FULLY PAID	175,769,548
EX1AE	OPTION EXPIRING 09-NOV-2025 EX \$1.00	600,000
EX1AF	OPTION EXPIRING 09-NOV-2025 EX \$1.50	600,000
EX1AG	OPTION EXPIRING 09-NOV-2025 EX \$2.25	600,000
EX1AL	OPTION EXPIRING 12-MAY-2026 EX \$0.025	1,200,000
EX1AM	OPTION EXPIRING 01-DEC-2027 EX \$0.0375	4,000,000
EX1AN	OPTION EXPIRING 01-DEC-2027 EX \$0.05	2,000,000
EX1AO	OPTION EXPIRING 01-DEC-2027 EX \$0.075	2,000,000

The Company further confirms that the Consolidation will conclude in accordance with remainder of the timetable as outlined in the Appendix 3A.3, as follows:

- Issue Date: 23 April 2024;
- Trading starts on a normal T+2 basis: 24 April 2024; and
- First settlement of trades conducted on a deferred settlement basis and on a normal T+2 basis: 29 April 2024

Updated holding statements will be despatched today to Shareholders and Optionholders.

—ENDS—

*This announcement was authorised for issue by the Chair of Exopharm Limited.*

For more information, please contact:

**Company enquiries**

David Franks  
Company Secretary  
Exopharm Limited  
P: +61 2 8098 1169

**Corporate enquiries**

Cameron Bolton  
Alto Capital  
P: +61 418 944 611

**About Exopharm Limited**

Exopharm (ASX:EX1) is a leader in advancing Genetic Medicines and other exosome-based medicines using exosomes or extracellular vesicles (EVs) as a chassis for improved and nonviral drug-delivery.

Exosomes can be loaded with a variety of active pharmaceutical ingredients (APIs) and can be targeted to selected cell-types and tissue types, improving the safety-profile of the APIs and providing better treatments. Exosomes can be used to deliver small molecule drugs, mRNA, DNA and other types of APIs.

Exosomes are an alternative means of drug-delivery inside the body, alongside technologies such as lipid nanoparticles (LNP), cell-penetrating peptides, viral vectors and liposomes. Exopharm's exosome technologies solve important needs for the success of exosome medicines – LEAP manufacturing technology, LOAD API loading technologies and EVPS tropism technologies.

Exosome-based medicines could improve the treatment of many chronic or inherited medical conditions. Exopharm is making its proprietary technologies available to pharmaceutical and biotechnology companies that want to harness exosome-delivery for their own products. Exopharm is also seeking to develop important exosome medicines itself.

**Forward Looking Statements**

Statements contained in this release, particularly those regarding possible or assumed future performance, revenue, costs, dividends, production levels or rates, prices or potential growth of Exopharm Limited, are, or may be, forward looking statements. Such statements relate to future events and expectations and, as such, involve known and unknown risks and uncertainties. Actual results and developments may differ materially from those expressed or implied by these forward-looking statements depending on a variety of factors.